ABT
FY2026 Q2 · Calendar Q3 2026
Abbott Laboratories
Abbott's Q2 2026 results mark a clear inflection from the prior quarter. Comparable sales growth accelerated to 4.8% (from 3.7% in Q1), and adjusted EPS of $1.31 beat the $1.28 consensus by 2.3%. Management raised full-year EPS guidance to $5.45–$5.60, reversing Q1's lowered posture. The market responded with an 11.3% abnormal move on 2.4x baseline volume, with continued upward drift since. The thesis now hinges on a second-half launch wave — Libre Duo, Amulet 360, Bolt 2.0, Tactiflex Duo, and new nutrition products — underpinned by Exact Sciences integration and a planned fifth billion-dollar sensor manufacturing facility.
EPS surprise+2.3%
Market move+10.7%
